Thu Sep 19 07:29:42 UTC 2024: ## Acadian Asset Management Boosts Stake in Werewolf Therapeutics Amidst Growing Investor Interest

**New York, NY – September 19, 2024** – Acadian Asset Management LLC has increased its holdings in Werewolf Therapeutics, Inc. (NASDAQ: HOWL) by 22.8% in the second quarter, according to a recent SEC filing. The fund now owns 212,296 shares of the company, valued at approximately $516,000.

Acadian’s move follows a trend of increased interest in Werewolf Therapeutics from other institutional investors. Janus Henderson Group PLC acquired a new stake worth $10.92 million in the first quarter, while Lighthouse Investment Partners LLC also established a new position valued at $87,000 during the fourth quarter. Vanguard Group Inc. significantly expanded its stake by 26.8% in the first quarter, now holding 1,107,347 shares worth $7.18 million. Denali Advisors LLC and PFM Health Sciences LP also joined the list of new investors, with stakes worth $172,000 and $13.39 million, respectively.

Institutional ownership in HOWL currently stands at 64.84%.

Several brokerages have issued positive ratings for Werewolf Therapeutics. HC Wainwright reiterated a “buy” rating with a $15.00 price objective, while Wedbush maintained an “outperform” rating and a $9.00 target price. JMP Securities also restated a “market outperform” rating with a $12.00 target price.

Despite missing analysts’ earnings estimates in the latest quarter, Werewolf Therapeutics continues to garner attention due to its focus on developing immune-stimulating therapies for cancer treatment. The company’s proprietary PREDATOR platform seeks to address the limitations of conventional immune therapies.

Werewolf Therapeutics’ stock opened at $2.22 on Thursday, with a 50-day moving average price of $2.31 and a 200-day moving average of $3.99. The company has a market cap of $96.47 million and a price-to-earnings ratio of -2.04.

**Analysts are predicting a loss of $1.64 per share for Werewolf Therapeutics in the current year.**

**About Werewolf Therapeutics**

Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity, addressing the limitations of conventional proinflammatory immune therapies.

Read More